 FRET-based assays demonstrate that the combination of two PLB mutations: L31A-PLB M (loss of inhibitory function) and I40A-PLB M (associated with increased SERCA binding), result in a PLB M (L31A/I40A) capable of displacing PLB WT .  Ectopic expression of the L31A/I40A-PLB M construct in HEK293-6E cells expressing PLB WT increased Ca-ATPase activity.  In hiPSC-CMs, direct measurement of the effect(s) of virally-delivered L31A/I40A-PLB M on SR Ca 2+ transport showed significantly enhancement in Ca-release amplitude and removal compared to controls.  rAAV2.L31A/I40A-PLB M corrected irregular Ca 2+ transients and improved Ca 2+ transport in a hereditary dilated cardiomyopathy model in hiPSC-CMs (R14del-PLB).  These results suggest that gene transfer of PLB M is viable therapy for cardiac diseases associated with impaired Ca 2+ transport and muscle contractility.
Abbreviations: Ca 2+ (calcium) DCM (dilated cardiomyopathy) ER (endoplasmic reticulum) FLT (fluorescence lifetime) FRET (fluorescence resonance energy transfer) GOI (gain of inhibitory functionbinding) GFP (green fluorescent protein) hiPSC-CM (human induced pluripotent stem cell-derived cardiomyocyte) HEK (human embryonic kidney) HF (heart failure) LOI (loss of inhibitory function) mAb (monoclonal antibody) miRNA (microRNA) pAb (polyclonal antibody) PLB (phospholamban) PLB M (phospholamban mutant) PLB WT (wild type phospholamban) rAAV (recombinant adeno-associated virus) RFP (red fluorescent protein) SERCA2a (sarcoendoplasmic reticulum calcium ATPase 2a) SR (sarcoplasmic reticulum)
Introduction
Heart failure (HF) is a pathology characterized by the impaired capacity of ventricles to fill with or eject blood, constituting a leading cause of morbidity and mortality worldwide. 1 Over the past few decades, researchers have made significant progress in identifying intracellular and molecular mechanisms that are altered during HF progression. Defective sarcoplasmic reticulum (SR) Ca 2+ transport has been identified as a potential determinant of decreased contractility in the failing hearts. [2] [3] [4] Ca 2+ transport from the cytosol to the SR lumen in human cardiomyocytes (CM) is largely performed (~70% of Ca 2+ ions transported) via the SR Ca-ATPase (SERCA2a). 5 Despite recent advances in device and pharmacological therapies, rates of heart disease continue to rise due to an aging population; thus, new treatment options are urgently needed. Increasing knowledge of the molecular mechanisms fundamental to cardiac diseaseincluding HFhas expanded the therapeutic potential to target key players involved in Ca 2+ handling, including SERCA2a.
The activity of SERCA2a is regulated by phospholamban (PLB), a 52-residue single-pass transmembrane protein expressed in the SR of cardiac muscle, which binds to SERCA2a and reduces its apparent Ca 2+ affinity. 6 PLB is in equilibrium between homopentamers and monomers, where the oligomeric state is proposed to function as a reservoir. 7 Previous studies have identified two functional regions on the transmembrane (TM) helix of PLB. [8] [9] [10] Single-residue mutations on one side of the TM helix diminish inhibitory function without significantly affecting PLB oligomerization state(s), whereas mutations on the other side of the TM helix modulate PLB oligomerization and can lead to enhanced SERCA inhibition. 8, 11 The regulation of gene expression has been investigated in healthy individuals and HF patients, and decreased SERCA-to-PLB ratio is associated with deteriorated cardiac function, indicating that SERCA/PLB stoichiometry and SERCA2a activity are potential therapeutic targets. [12] [13] [14] To this end, SERCA2a transgene expression via recombinant adeno-associated virus (rAAV) was achieved in HF animal models to increase the SERCA-to-PLB ratio in the heart. Exogenous SERCA2a expression was tolerated and significantly enhanced cardiac function in disease models by multiple metrics. 15, 16 Recently, gene therapy designed to increase SERCA2a expression in the heart underwent clinical trials in patients diagnosed with end-stage HF. 17 Despite positive preliminary results in Phase 1/2a, 18 the trial did not meet its primary end goals in phase 2b and this has been ascribed to dosage constraints. 19 One factor may be the large size of SERCA2a, which limits steady-state expression levels of the gene therapy construct. Other promising strategies to increase the SERCA-to-PLB ratio include expression of miRNAs that directly target PLB expression [20] [21] [22] and oligonucleotide-based drugs 23, 24 , although these strategies have not yet produced an effective therapeutic agent.
In this study, we have pursued an alternative approach to activate SERCA2a by expressing a loss-ofinhibition (LOI) PLB mutant (PLB M ) that is engineered to compete with the inhibitory wild type PLB (PLB WT ) ( Fig. 1A ) via viral delivery. In this approach, the ratio between endogenous SERCA and PLB is not targeted, rather the endogenous inhibitory PLB WT is competed by PLB M to relieve SERCA2a inhibition and enhance its Ca 2+ transport function. Thus, this strategy is designed to overcome limitations associated with SERCA2a overexpression-based gene therapy.
Materials and methods

Molecular biology
eGFP and tagRFP were fused to the N-terminus of human SERCA2a and human PLB, respectively. We have demonstrated that attachment of the fluorescent proteins at these sites does not interfere with SERCA activity or PLB inhibition. 25, 26 PLB cDNA mutations were introduced using the QuikChange mutagenesis kit (Agilent Technologies, Santa Clara, CA), and all expression plasmids were sequenced for confirmation.
Cell culture
Human embryonic kidney cells 293 (HEK293-6E, NRC, Canada) were cultured in FreeStyle F17 expression medium (Thermo Fisher Scientific, Waltham, MA) supplemented with 2 mM L-glutamine (Invitrogen, Waltham, MA). Cell cultures were maintained in a circular shaker (125 rpm, 37°C, 5% CO 2 (Forma Series II Water Jacket CO 2 Incubator, Thermo Fisher Scientific, Waltham, MA). For displacement assays, HEK293-6E cells were transiently transfected using 293fectamine with GFP-SERCA2a, RFP-PLB WT , and PLB M or empty vector in a 1:7:7 molar ratio. Cells were then assayed 48 hours post-transfection.
The control hiPSC line (SKiPS-31.3) was cultured as previously described. 27 The R14del hiPSC line was derived from the SKiPS-31.3 line using homologous recombination via CRISPR/Cas9. Monolayer cardiac differentiation was performed as described, 27 yielding beating cardiomyocytes within 7-10 days.
Gene expression
RNA was extracted from uninfected and rAAV-infected hiPSC-CMs at day 25, and cDNA was synthesized as previously described. 27 Gene expression compared to the housekeeping gene β2-microglobulin was determined using qRT-PCR, as assessed by ΔΔC t analysis. See Supplemental Table 1 for the list of primers.
Immunoblot analysis
Samples were separated on a 4-20% polyacrylamide gradient gel (Bio-Rad, Hercules, CA) and transferred to polyvinylidene difluoride (PVDF) membrane. The PVDF membrane was blocked in Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE) followed by overnight incubation at 4 °C with the primary target antibody: rabbit anti-GFP polyclonal antibody (pAb) (1:1000; ab290, Abcam, Cambridge, United Kingdom), mouse anti-SERCA2 monoclonal antibody (mAb) (1:1000; 2A7-A1, Abcam), rabbit anti-tagRFP pAb (1:1000; ab233, Evrogen), mouse anti-PLB mAb (1:1000, 2D12, Abcam), or rabbit anti-β-actin pAb (1:5000, ab8227, Abcam). Blots were incubated with anti-mouse or anti-rabbit secondary antibodies conjugated to IRDye 680RD or IRDye 800CW, respectively, for 1 h at 23 °C (1:20,000; LI-COR Biosciences). Blots were quantified on the Odyssey scanner (LI-COR Biosciences).
Fluorescence data acquisition and analysis
Fluorescence lifetime (FLT) measurements were conducted in a top-read FLT plate reader designed and built by Fluorescence Innovations, Inc. (St. Paul, MN) in 384-well plate formats. GFP donor fluorescence was excited with a 473 nm microchip laser from Concepts Research Corporation (Belgium, WI), and emission was acquired with 490 nm long-pass and 520/17 nm band-pass filters (Semrock, Rochester, NY). We previously validated the performance of this FLT plate reader with known fluorescence standards, as well as with a FRET-based highthroughput screening strategy that that targeted 2-color SERCA. 28, 29 FLT waveforms from donor-and donor/acceptor-labeled samples were analyzed as described in our previous publications and the supplemental methods. 28, 29 
Ca-ATPase activity assay
An enzyme-coupled, NADH-linked ATPase assay was used to measure Ca 2+ -activated ATPase activity of SERCA in 96-well microplates. Each well contained HEK293-6E homogenates, 50 mM MOPS (pH 7.0), 100 mM KCl, 1 mM EGTA, 0.2 mM NADH, 1 mM phosphoenol pyruvate, 10 IU/mL of pyruvate kinase, 10 IU/mL of lactate dehydrogenase, 3.5 μg/mL of the Ca 2+ ionophore A23187, and CaCl 2 added to set [Ca 2+ ] i to the desired values. 11 The assay was started by addition of Mg-ATP at a final concentration of 5 mM, and well absorbances were read in a SpectraMax 384 Plus microplate spectrophotometer (Molecular Devices, Sunnyvale, CA). The Ca-ATPase assays were conducted over a range of [Ca 2+ ] i , and the ATPase activities were fitted using the Hill function where V is the initial rate of Ca 2+ -dependent ATPase activity at a specified Ca 2+ concentration (pCa), V max is the rate of Ca-ATPase activity at saturating [Ca 2+ ] i , n is the Hill coefficient, pK Ca is the fitted Ca 2+ dissociation constant, and pCa is the concentration of ionized Ca 2+ per specific well and V.
Live-cell Ca 2+ transient measurements
hiPSC-CMs (day 25 of differentiation) were enzymatically dissociated using the Detach 2 kit (Promocell, Heidelberg, Germany) and plated on Matrigel-coated German glass coverslips. After 2 days, the plated hiPSC-CMs were loaded with a Ca 2+ -sensitive fluorescent dye (Fura-2 AM, cell permeant, ThermoFisher, Rockville,
Eq. (1)
MD, USA), and the ratio of fluorescence intensities (excitation ratio of 340/380 nm) were recorded using the IonOptix system (Ionoptix, Milton, MA). The electrically-induced Ca 2+ transients were triggered by pulses from a MyoPacer (IonOptix, Milton, MA) at 40 V and 0.5 Hz, with cells at 23 °C. Ca 2+ traces were analyzed using IonWizard software (IonOptix) to calculate the release amplitude (peak height relative to baseline) and tau (time of Ca 2+ removal). The number of irregular Ca 2+ transients was quantified using IonOptix software. Using rAAV2.L31A, rAAV2.I40A, and rAAV2.L31A/I40A PLB viruses, hiPSC-CMs were infected at day 20 of differentiation (1e4 MOI), enzymatically dissociated on day 23, and plated on Matri-gel coated German glass coverslips, as described above. Fura-2 fluorescence measurements were recorded in AAV-infected hiPSC-CMs on day 25 and compared to non-infected control hiPSC-CMs. AAV viruses were purified according to the two-plasmid method with iodixanol gradient as described. 30 
Statistical analyses
All statistics were performed using Prism (GraphPad, La Jolla, CA), and analysis was done by one-way ANOVA followed by the Bonferroni post hoc test; analysis of two group comparisons was done by Student's ttest (*P < 0.05, **P < 0.01, ***P < 0.001, # P < 0.0001, and 'ns' is not significant). Data is presented as mean ± standard error of the mean (SEM), and all statistical values were calculated from a minimum of three separate experiments.
Results
FRET assay demonstrates SERCA-binding competition between PLB WT and loss-of-function PLB M
Previously, two classes of point mutations within the PLB TM domain had been identified via alaninescanning mutagenesis with disparate functional outcomes: loss-of-inhibitory function (LOI) and gain-ofinhibitory function (GOI). 8 We hypothesized that combining LOI and GOI mutations in a single PLB would result in a LOI-PLB that can effectively compete with the inhibitory PLB WT . To test this, we used a SERCA2a-PLB biosensor system that consists of co-expressed GFP-tagged SERCA2a and RFP-tagged PLB WT in HEK293-6E cells and a fluorescence lifetime (FLT) readout of FRET. FLT-FRET is used to resolve changes in SERCA2a-PLB complex structure and binding. 28 We varied the ratio between the donor molecule (GFP-SERCA2a) and acceptor molecule (RFP-PLB WT ), and found that the maximal energy transfer efficiency E (fractional decrease of the fluorescence lifetime) in this live-cell based system saturates at 0.10, as previously reported. 28 We transfected cells expressing GFP-SERCA2a and RFP-PLB WT with either untagged PLB WT or PLB M containing TM mutations (L31A, I40A, or L31A/I40A). Displacement of the RFP-PLB WT from its interaction with GFP-SERCA2a was observed as a decrease in the FRET efficiency relative to that measured in control cells expressing only the GFP-SERCA/RFP-PLB WT donor-acceptor pair (Fig. 1B) . FRET between GFP-SERCA2a and RFP-PLB WT decreased significantly upon co-expression of unlabeled PLB WT , indicating that the RFP-PLB WT and unlabeled PLB WT are in equilibrium for hetero-dimeric binding to GFP-SERCA2a. An alanine substitution at L31A (LOI mutation) did not significantly alter the FRET value relative to the wild-type control. In contrast, an alanine substitution at I40A (associated with increased SERCA inhibition via decreased Ca 2+ sensitivity) further decreased FRET, indicating that I40A-PLB M competes effectively with RFP-PLB WT with a potency (affinity) comparable to or greater than that of unlabeled PLB WT . The combination of L31A andI40A mutations resulted in a PLB M with potency similar to that of I40A-PLB M , supporting our hypothesis that PLB M with both mutation types retains high affinity toward SERCA2a.
Expression of the constructs was confirmed by SDS-PAGE and immunoblot in "boiled" samples, which disrupts PLB pentamers, vs. non-"boiled" heated samples, which maintains the pentameric PLB state (Fig. 1C,  D) . GFP-tagged SERCA2a was resolved from endogenous SERCA2b, as verified by binding of a GFP-specific antibody. There were no bands of lower mobility and no apparent aggregation in intact cells. Expression of RFP-PLB produced a single band recognized by RFP-and PLB-specific antibodies. The I40A mutation disrupts pentamer formation, and we observed the disappearance of the band corresponding to PLB M pentamer when the I40A mutation is present (Fig. 1D; lanes 11 and 12) . PLB pentamer was detected for PLB WT and L31A-PLB ( Fig. 1D; lanes 13 and14 ). As the expression of GFP-SERCA2a, RFP-PLB WT , and PLB M is not significantly different between respective samples, the observed changes in FRET are probably due to displacement of the RFP-tagged PLB WT via competition (to GFP-SERCA2a) by untagged PLB M . The Ca-ATPase function of GFP-SERCA is similar to untagged SERCA, so the tag does not disrupt endogenous function. 26 
Effects of loss-of-function and gain-of-binding PLB mutants on SERCA2a regulation
The effects of PLB M overexpression on the apparent Ca 2+ affinity of SERCA2a were determined in HEK293-6E homogenate samples, enabling co-expression of PLB WT and PLB M in a cell-based system similar to the FRET assays. Ca-ATPase activity in HEK293-6E cells expressing SERCA2a alone ( Fig. 2A, black) increases with Ca 2+ at physiological Ca 2+ concentrations (e.g., between pCa 7 and pCa 6) and saturates at higher Ca 2+ concentrations (pCa 5), consistent with previous measurements. 28 Concomitant expression of PLB WT ( Fig.  2A,B , dark gray) decreases the apparent Ca 2+ affinity of SERCA2a, and the additional expression of PLB WT (light blue) or L31A-PLB M (light gray) does not significantly decrease the apparent Ca 2+ affinity; indicating that SERCA2a is fully inhibited and that L31A-PLB M is not sufficient to relieve PLB WT inhibition under these experimental conditions. We observed a further decrease in the apparent Ca 2+ affinity upon co-expression of SERCA2a, PLB WT , and I40A-PLB M (red), suggesting that I40A-PLB M binds to SERCA2a in the presence of PLB WT (consistent with FRET measurements) and acts as a super-inhibitor. Co-expression with L31A/I40A-PLB M (green) increased Ca 2+ affinity to values similar to the SERCA-only sample, indicating that the PLB inhibition was relieved. Taken together, the structural (FRET) and functional (Ca-ATPase) assay results demonstrate that L31A/I40A-PLB M is non-inhibitory and binds to SERCA2a in HEK293-6E cells.
rAAV-driven expression of L31A/I40A-PLB M enhances Ca 2+ transients in hiPSC-CMs
We differentiated hiPSCs derived from a healthy individual (SKiPS-31.3 line) into cardiomyocytes using established protocols that yields a predominant ventricular-like population. 27 To assess physiological relevance in this native SERCA-PLB cardiac system, we tested the effects of rAAV-delivered PLB M by infecting hiPSC-CMs with empty virus, rAAV2.L31A-, rAAV2.I40A-, or rAAV2.L31A/I40A-PLB M at day 20 of differentiation and recording Ca 2+ transients via fura-2AM upon electrical stimulation at day 25 (Fig. 3A) . Ca 2+ transients were regular in appearance (Fig. 3B ). hiPSC-CMs expressing rAAV2.L31A-PLB M or rAAV2.I40A-PLB M did not show significant changes in peak amplitude or the rate of Ca 2+ removal relative to control cells expressing empty vector (Fig. 3C ). However, there were striking improvements in Ca 2+ transient parameters (increased peak amplitude, increased Ca 2+ removal rate) in hiPSC-CMs infected with rAAV2.L31A/I40A-PLB M (Fig. 3B and C) . Expression of the exogenous PLB M was confirmed by qRT-PCR where virally-infected hiPSC-CMs had approximately two PLB M per one PLB WT (Fig. 3D) . We observed no differences in SERCA2a or cardiac Troponin T expression levels (Fig. 3D ).
Relief of SERCA2a inhibition by PLB M rescues irregular Ca 2+ transients in cardiomyopathic R14del-PLB hiPSC-CMs
Autosomal dominant mutations in PLB have been linked to DCM and these mutations include R9C 31 , R14del 32-34 , R25C 35 , and L39stop 36 . Recent work using hiPSC-CMs derived from patients heterozygous for the R14del-PLB mutation show mislocalization of R14del-PLB into aggregates leading to higher levels of autophagy and accompanying irregular Ca 2+ transients. 37, 38 Mice heterozygous for the R14del-PLB mutation have severe defects in SERCA2a activity and Ca 2+ transport. We sought to characterize the effects of viral expression of PLB M in this dilated cardiomyopathic model to evaluate therapeutic potential. To accomplish this, we generated a R14del-PLB knock-in hiPSC line using homologous recombination via CRISPR/Cas9 to insert the R14del-PLB mutation into the control SKiPS-31.3 line (Fig. 3) , producing an isogenic control to test our therapies. 27 The R14del-PLB hiPSC-CMs exhibited an arrhythmic (irregular) Ca 2+ transient profile 37 after day 35 of differentiation, characterized by a failure to respond to electric stimulation. This irregularity occurred at a frequency of 58 ± 19% of Ca 2+ transient recorded under basal conditions. (n = 85 cells) ( Fig. 4A/D) . Upon infection with rAAV2.L31A/I40A-PLB, we observed an improvement in Ca 2+ handling properties of the R14del-PLB hiPSC-CMs. Representative Ca 2+ tracings show a significant reduction in irregular Ca 2+ transients and improvements in Ca 2+ amplitude and tau upon rAAV2.L31A/I40A-PLB infection (Fig. 4B/C) . Finally, no irregular Ca 2+ transients (n = 20 cells) were observed after infection with rAAV2.L31A/I40A-PLB (Fig. 4D) . Altogether, these data indicate an impairment in Ca 2+ cycling in R14del-PLB hiPSC-CMs that is corrected by exogenous expression of the SERCA activating L31A/I40A-PLB M .
Discussion
We demonstrated previously that the interaction between the cardiac Ca 2+ pump, SERCA2a, and its inhibitor, PLB, can be measured via FRET in HEK293 cell system. 28 In the present study, we applied this FRET assay to measure the competition of non-inhibitory PLB M and RFP-labeled PLB WT for binding to the GFP-SERCA2a. We used this assay to measure the relative affinity of non-inhibitory PLB M and identified a double mutant (L31A/I40A) that binds with affinity greater than PLB WT . Expression of L31A/I40A-PLB M increased Ca-ATPase activity in PLB WT -expressing HEK293 cells. Mechanistically, this suggests that L31A/I40A-PLB M enhances SERCA activity by competitively displacing the inhibitory form of PLB. There were previous attempts to increase SR Ca-influx in HF-animal models by expressing non-inhibitory PLB M , including a pseudophosphorylated mutant (S16E) 39 and a dominant-negative mutant (R3E/R14E) 40 . Although there were significant improvements in Ca transients and cardiac output, these mutations preclude PLB phosphorylation by PKA and -adrenergic stimulation. 39, 40 In hiPSC-CMs, we found that rAAV2-dependent expression of L31A/I40A-PLB M significantly improved Ca 2+ release amplitude and removal in both healthy and pathogenic cell lines. This work paves the way for a potential therapeutic for heart diseases associated with impaired Ca 2+ transport and decreased contractility. 
Supplementary Methods:
Fluorescence Data Acquisition and Analysis 28 The measured FLT waveform is a function of the nanosecond decay time t, and is modeled as the convolution integral of the measured instrument response function, IRF(t), and the fluorescence decay model, F(t). The fluorescence decay model is a linear combination of a donor-only fluorescence decay function F D (t) and an energy transfer-decreased donor fluorescence decay F DA (t). The donor decay F D (t) is a sum of n exponentials with discrete FLT species  i and pre-exponential mole fractions A i . For the GFP donor, two exponentials (n = 2) are required to fit the observed fluorescence decay waveform. The energy transfer-decreased donor decay function, F DA (t), is the sum of the distribution of multiple structural states (j) with mole fractions X j , represented by the FRETquenched donor fluorescence decays T j (t). The increase in the donor decay rate (inverse donor FLT) due to FRET is given by the Förster equation Supplementary Table 1 . Primers used in qPCR.
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